Subtyping of ALL via advance genetic profiling methods can better identify aberrations sensitive to current FDA-approved PI3K inhibitors in order to improve therapeutic approaches in the treatment of ALL. The gene discussed is PIK3CA; the disease is acute lymphoblastic leukemia.